RÉSUMÉ
Peripheral neurotoxicity is a dose-limiting adverse reaction of primary frontline chemotherapeutic agents, including vincristine. Neuropathy can be so disabling that patients drop out of potentially curative therapy, negatively impacting cancer prognosis. The hallmark of vincristine neurotoxicity is axonopathy, yet its underpinning mechanisms remain uncertain. We developed a comprehensive drug discovery platform to identify neuroprotective agents against vincristine-induced neurotoxicity. Among the hits identified, SIN-1-an active metabolite of molsidomine-prevents vincristine-induced axonopathy in both motor and sensory neurons without compromising vincristine anticancer efficacy. Mechanistically, we found that SIN-1's neuroprotective effect is mediated by activating soluble guanylyl cyclase. We modeled vincristine-induced peripheral neurotoxicity in rats to determine molsidomine therapeutic potential in vivo. Vincristine administration induced severe nerve damage and mechanical hypersensitivity that were attenuated by concomitant treatment with molsidomine. This study provides evidence of the neuroprotective properties of molsidomine and warrants further investigations of this drug as a therapy for vincristine-induced peripheral neurotoxicity.
Sujet(s)
Molsidomine , Neuroprotecteurs , Soluble guanylyl cyclase , Vincristine , Vincristine/effets indésirables , Vincristine/pharmacologie , Vincristine/toxicité , Animaux , Neuroprotecteurs/pharmacologie , Rats , Soluble guanylyl cyclase/métabolisme , Molsidomine/pharmacologie , Molsidomine/analogues et dérivés , Humains , Mâle , Neuropathies périphériques/induit chimiquement , Neuropathies périphériques/prévention et contrôle , Neuropathies périphériques/traitement médicamenteux , Rat Sprague-Dawley , Syndromes neurotoxiques/traitement médicamenteux , Syndromes neurotoxiques/prévention et contrôle , Syndromes neurotoxiques/métabolisme , Syndromes neurotoxiques/étiologieRÉSUMÉ
Cancer is the leading cause of disease-related death among children. Vincristine (VCR), a key component of childhood cancer treatment protocols, is associated with the risk of peripheral neuropathy (PN), a condition that may be reversible upon drug discontinuation but can also leave lasting sequelae. Single nucleotide polymorphism (SNP) in genes involved in VCR pharmacokinetics and pharmacodynamics have been investigated in relation to an increased risk of PN. However, the results of these studies have been inconsistent. A retrospective cohort study was conducted to investigate the potential association of drug transporter genes from the ATP-binding cassette (ABC) family and the centrosomal protein 72 (CEP72) gene with the development of PN in 88 Caucasian children diagnosed with cancer and treated with VCR. Genotyping was performed using real-time PCR techniques for the following SNPs: ABCB1 rs1128503, ABCC1 rs246240, ABCC2 rs717620, and CEP72 rs924607. The results indicated that age at diagnosis (OR = 1.33; 95% CI = 1.07-1.75) and the ABCC1 rs246240 G allele (OR = 12.48; 95% CI = 2.26-100.42) were associated with vincristine-induced peripheral neuropathy (VIPN). No association was found between this toxicity and CEP72 rs924607. Our study provides insights that may contribute to optimizing childhood cancer therapy in the future by predicting the risk of VIPN.
Sujet(s)
Protéine-2 associée à la multirésistance aux médicaments , Protéines associées à la multirésistance aux médicaments , Tumeurs , Neuropathies périphériques , Polymorphisme de nucléotide simple , Médecine de précision , Vincristine , Humains , Vincristine/effets indésirables , Vincristine/usage thérapeutique , Neuropathies périphériques/induit chimiquement , Neuropathies périphériques/génétique , Enfant , Femelle , Mâle , Protéines associées à la multirésistance aux médicaments/génétique , Enfant d'âge préscolaire , Médecine de précision/méthodes , Tumeurs/traitement médicamenteux , Tumeurs/génétique , Adolescent , Études rétrospectives , Protéines du cycle cellulaire/génétique , Nourrisson , Antinéoplasiques d'origine végétale/effets indésirables , Antinéoplasiques d'origine végétale/usage thérapeutique , Prédisposition génétique à une maladie , Génotype , Allèles , Sous-famille B de transporteurs à cassette liant l'ATP/génétique , Protéines associées aux microtubulesRÉSUMÉ
Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with untreated RT of diffuse large B-cell lymphoma histology (NCT03931642). In this multicentre phase 2 study, patients without complete response (CR) after two cycles of R-CHOP were eligible to receive an 8-week blinatumomab induction via continuous vein infusion with stepwise dosing until 112 µg/day. The primary endpoint was the CR rate after blinatumomab induction and secondary endpoint included safety, response duration, progression-free and overall survival. Thirty-nine patients started the first cycle of R-CHOP, 25 of whom received blinatumomab. After blinatumomab induction, five (20%) patients achieved CR, four (16%) achieved partial response, and six (24%) were stable. Considering the entire strategy, the overall response rate in the full-analysis-set was 46% (n = 18), with CR in 14 (36%) patients. The most common treatment-emergent adverse events of all grades in the blinatumomab-safety-set included fever (36%), anaemia (24%), and lymphopaenia (24%). Cytokine release syndrome (grade 1/2) was observed in 16% and neurotoxicity in 20% of patients. Blinatumomab demonstrated encouraging anti-tumour activity (the trial met its primary endpoint) and acceptable toxicity in patients with RT.
Sujet(s)
Anticorps bispécifiques , Protocoles de polychimiothérapie antinéoplasique , Cyclophosphamide , Doxorubicine , Lymphome B diffus à grandes cellules , Prednisone , Rituximab , Vincristine , Humains , Mâle , Femelle , Anticorps bispécifiques/administration et posologie , Anticorps bispécifiques/effets indésirables , Anticorps bispécifiques/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Adulte d'âge moyen , Cyclophosphamide/usage thérapeutique , Cyclophosphamide/administration et posologie , Cyclophosphamide/effets indésirables , Rituximab/administration et posologie , Rituximab/usage thérapeutique , Rituximab/effets indésirables , Doxorubicine/usage thérapeutique , Doxorubicine/administration et posologie , Doxorubicine/effets indésirables , Sujet âgé , Prednisone/usage thérapeutique , Prednisone/administration et posologie , Prednisone/effets indésirables , Vincristine/usage thérapeutique , Vincristine/effets indésirables , Vincristine/administration et posologie , Lymphome B diffus à grandes cellules/traitement médicamenteux , Adulte , Sujet âgé de 80 ans ou plus , Leucémie chronique lymphocytaire à cellules B/traitement médicamenteux , Résultat thérapeutiqueRÉSUMÉ
The low incidence of vincristine-induced peripheral neuropathy (VIPN) in Kenyan children may result from low vincristine exposure. We studied vincristine exposure in Kenyan children and dose-escalated in case of low vincristine exposure (NCT05844670). Average vincristine exposure was high. Individual vincristine exposure was assessed with a previously developed nomogram. A 20% dose increase was recommended for participants with low exposure and no VIPN, hyperbilirubinemia, or malnutrition. None of the 15 participants developed VIPN. Low vincristine exposure was seen in one participant: a dose increase was implemented without side effects. In conclusion, the participants did not develop VIPN despite having high vincristine exposure.
Sujet(s)
Études de faisabilité , Neuropathies périphériques , Vincristine , Humains , Vincristine/effets indésirables , Vincristine/administration et posologie , Femelle , Mâle , Kenya , Enfant d'âge préscolaire , Enfant , Neuropathies périphériques/induit chimiquement , Nourrisson , Antinéoplasiques d'origine végétale/effets indésirables , Antinéoplasiques d'origine végétale/administration et posologie , Tumeurs/traitement médicamenteux , Études de suivi , AdolescentRÉSUMÉ
Vincristine (VCR) is one of the most widely used chemotherapy agents in treating pediatric cancer. Nonetheless, it is known to cause dose-dependent neurotoxicity which can impact virtually every organ system. Despite its widespread use, the precise impact of VCR on the lower urinary tract (LUT) remains inadequately elucidated. Our initial clinical and translational investigations suggest a sex-specific influence of childhood VCR exposure on LUT function. Thus, the current study aimed to investigate the late effects of systemic VCR exposure on LUT physiology and the underlying mechanisms, focusing on dosage and male-sex, employing juvenile CD-1 mice as a model. Male mice subjected to VCR exhibited augmented functional bladder capacity accompanied by frequent non-void contractions during awake cystometry, alongside mast cell accumulation within the bladder, compared to the saline-treated control group. Noteworthy functional changes were observed in bladder strips from the VCR group, including decreased nerve-mediated contraction, heightened contractile responses to cholinergic and purinergic agonists, enhanced responsiveness to histamine-primarily via histamine receptor 1 (Hrh1)-and an augmented relaxation effect with compound 48/80 (a mast cell degranulator), relative to the control group. Significant changes in gene expression levels associated with neuroinflammation and nociception were observed in both the bladder and lumbosacral dorsal root ganglia (Ls-DRG) of the VCR group. These findings suggest that VCR exposure during childhood, particularly in males, triggers neuroimmune responses in the bladder and Ls-DRG, amplifying responsiveness to neurotransmitters in the bladder, thereby contributing to LUT dysfunction characterized by a mixed bladder phenotype as a late effect during survivorship.
Sujet(s)
Vessie urinaire , Vincristine , Animaux , Mâle , Souris , Vessie urinaire/effets des médicaments et des substances chimiques , Vessie urinaire/anatomopathologie , Femelle , Vincristine/effets indésirables , Vincristine/pharmacologie , Mastocytes/effets des médicaments et des substances chimiques , Mastocytes/métabolisme , Humains , Facteurs sexuels , Relation dose-effet des médicaments , Antinéoplasiques d'origine végétale/effets indésirables , Antinéoplasiques d'origine végétale/pharmacologieRÉSUMÉ
INTRODUCTION: Ewing sarcoma (ES), is a rare cancer affecting children, adolescents and adults. After VIDE (vincristine-ifosfamide-doxorobucin-etoposide) induction chemotherapy, Busulfan-Melphalan (BuMel) high-dose chemotherapy followed by autologous hematopoietic stem cells transplantation improved outcomes in unfavourable localized ES, but with more toxicities than conventional chemotherapy (VAI: Vincristine-dactinomycin-Ifosfamide). We evaluated whether the risk of acute toxicity associated with BuMel compared to VAI varied according to age in patients recruited in the R2Loc and R2Pulm randomised trials of the Euro-E.W.I.N.G.99 and Ewing-2008 trials. METHODS: We included patients with a localized high-risk disease, or pulmonary or pleural metastasis. We analysed the risk of severe toxicity according to randomised treatment group (VAI versus BuMel) and age group (<12 years, 12-17 years, 18-24 years, ≥25 years). We evaluated the heterogeneity of treatment effects by age group using interaction terms in logistic multivariable models. RESULTS: The analysis included 243 patients treated with VAI and 205 with BuMel. Overall, BuMel was associated with a higher risk of severe acute toxicity than VAI particularly haematological, gastrointestinal, liver, sinusoidal occlusive syndrome, and infections. Severe haematological toxicity and lower general condition were significantly more frequent in younger patients, whatever treatment. We did not observe any significant heterogeneity in terms of the excess risk of severe toxicities associated with BuMel compared to VAI according to age group. CONCLUSION: The excess of acute toxicity associated with BuMel compared to VAI does not vary significantly with age, suggesting the feasibility of BuMel across all age groups.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique , Busulfan , Transplantation de cellules souches hématopoïétiques , Melphalan , Sarcome d'Ewing , Transplantation autologue , Humains , Transplantation de cellules souches hématopoïétiques/méthodes , Transplantation de cellules souches hématopoïétiques/effets indésirables , Sarcome d'Ewing/traitement médicamenteux , Sarcome d'Ewing/thérapie , Busulfan/administration et posologie , Busulfan/effets indésirables , Enfant , Adolescent , Jeune adulte , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Melphalan/administration et posologie , Melphalan/effets indésirables , Melphalan/usage thérapeutique , Mâle , Femelle , Facteurs âges , Adulte , Étoposide/administration et posologie , Étoposide/effets indésirables , Tumeurs osseuses/traitement médicamenteux , Tumeurs osseuses/secondaire , Vincristine/effets indésirables , Vincristine/administration et posologie , Vincristine/usage thérapeutique , Enfant d'âge préscolaire , Ifosfamide/administration et posologie , Ifosfamide/effets indésirables , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Multidrug chemotherapy for Ewing sarcoma can lead to severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, "Does primary prophylaxis with G-CSF benefit chemotherapy for Ewing sarcoma?" and CQ #2, "Does G-CSF-based intensified chemotherapy improve Ewing sarcoma treatment outcomes?". METHODS: A comprehensive literature search was conducted in PubMed, Cochrane Library, and Ichushi web databases, including English and Japanese articles published from 1990 to 2019. Two reviewers assessed the extracted papers and analyzed overall survival (OS), febrile neutropenia (FN) incidence, infection-related mortality, quality of life (QOL), and pain. RESULTS: Twenty-five English and five Japanese articles were identified for CQ #1. After screening, a cohort study of vincristine, ifosfamide, doxorubicin, and etoposide chemotherapy with 851 patients was selected. Incidence of FN was 60.8% with G-CSF and 65.8% without; statistical tests were not conducted. Data on OS, infection-related mortality, QOL, or pain was unavailable. Consequently, CQ #1 was redefined as a future research question. As for CQ #2, we found two English and five Japanese papers, of which one high-quality randomized controlled trial on G-CSF use in intensified chemotherapy was included. This trial showed trends toward lower mortality and a significant increase in event-free survival for 2-week interval regimen with the G-CSF primary prophylactic use compared with 3-week interval. CONCLUSION: This review indicated that G-CSF's efficacy as primary prophylaxis in Ewing sarcoma, except in children, is uncertain despite its common use. This review tentatively endorses intensified chemotherapy with G-CSF primary prophylaxis for Ewing sarcoma.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique , Facteur de stimulation des colonies de granulocytes , Sarcome d'Ewing , Humains , Sarcome d'Ewing/traitement médicamenteux , Facteur de stimulation des colonies de granulocytes/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Japon , Tumeurs osseuses/traitement médicamenteux , Guides de bonnes pratiques cliniques comme sujet , Doxorubicine/usage thérapeutique , Doxorubicine/effets indésirables , Doxorubicine/administration et posologie , Qualité de vie , Étoposide/usage thérapeutique , Étoposide/administration et posologie , Ifosfamide/usage thérapeutique , Ifosfamide/effets indésirables , Ifosfamide/administration et posologie , Oncologie médicale/méthodes , Vincristine/usage thérapeutique , Vincristine/effets indésirablesRÉSUMÉ
BACKGROUND: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the first line treatments for diffuse large B-cell lymphoma (DLBCL). Rituximab comprises most of the treatment cost for this regimen; therefore, biosimilars, such as rituximab-abbs are crucial to provide affordable care. Although rituximab-abbs was studied primarily in follicular lymphoma, the Food and Drug Administration (FDA) approved this drug for all indications of the reference product on the basis of extrapolation. Effectiveness and safety data surrounding the use of rituximab-abbs in DLBCL is lacking. OBJECTIVE: To evaluate the effectiveness and safety of rituximab-abbs and reference product rituximab as R-CHOP treatment for patients with DLBCL. PATIENTS AND METHODS: This noninferiority (NI) study compared the 2-year overall survival (OS), overall response rate (ORR), and incidence of adverse events (AEs) between rituximab-abbs and its reference product (RP) in R-CHOP among adult patients with newly diagnosed DLBCL. The study inclusion period was from 1 January 2019 to 31 December 2020. Analyses were performed on the basis of a noninferiority lower limit of 10% for OS and ORR, and an upper limit of 10% for serious AEs. RESULTS: There were 240 patients who received RP rituximab, while 295 patients received rituximab-abbs. The cohort had a mean age of 63.7±12.2 years and 43% were female. The 2-year OS was 81.0% and 79.6% (NI p < 0.01) while the ORR was 80.0% and 69.6% (NI p < 0.01), among the rituximab-abbs and rituximab groups, respectively. The incidence of infusion reaction AEs (NI p < 0.01) and noninfusion reaction AEs (NI p < 0.01) also met noninferiority. CONCLUSIONS: We demonstrated that rituximab-abbs was noninferior to rituximab in both effectiveness and safety among patients receiving R-CHOP for DLBCL in this study. Long-term follow-up would be needed to confirm these results.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique , Cyclophosphamide , Doxorubicine , Lymphome B diffus à grandes cellules , Prednisone , Rituximab , Vincristine , Humains , Rituximab/usage thérapeutique , Rituximab/effets indésirables , Rituximab/administration et posologie , Lymphome B diffus à grandes cellules/traitement médicamenteux , Femelle , Adulte d'âge moyen , Mâle , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Doxorubicine/usage thérapeutique , Doxorubicine/effets indésirables , Doxorubicine/administration et posologie , Cyclophosphamide/usage thérapeutique , Cyclophosphamide/effets indésirables , Cyclophosphamide/administration et posologie , Sujet âgé , Prednisone/usage thérapeutique , Prednisone/administration et posologie , Prednisone/effets indésirables , Vincristine/usage thérapeutique , Vincristine/effets indésirables , Vincristine/administration et posologie , Adulte , Produits pharmaceutiques biosimilaires/usage thérapeutique , Produits pharmaceutiques biosimilaires/effets indésirables , Produits pharmaceutiques biosimilaires/administration et posologie , Résultat thérapeutique , Sujet âgé de 80 ans ou plusRÉSUMÉ
BACKGROUND: The Children's Oncology Group defines intermediate-risk rhabdomyosarcoma as unresected FOXO1 fusion-negative disease arising at an unfavourable site or non-metastatic FOXO1 fusion-positive disease. Temsirolimus in combination with chemotherapy has shown promising activity in patients with relapsed or refractory rhabdomyosarcoma. We aimed to compare event-free survival in patients with intermediate-risk rhabdomyosarcoma treated with vincristine, actinomycin, and cyclophosphamide alternating with vincristine and irinotecan (VAC/VI) combined with temsirolimus followed by maintenance therapy versus VAC/VI alone with maintenance therapy. METHODS: ARST1431 was a randomised, open-label, phase 3 trial conducted across 210 institutions in Australia, Canada, New Zealand, and the USA. Eligible patients were those aged 40 years or younger with non-metastatic FOXO1-positive rhabdomyosarcoma or unresected FOXO1-negative rhabdomyosarcoma disease from unfavourable sites. Two other groups of patients were also eligible: those who had FOXO1-negative disease at a favourable site (excluding orbit) that was unresected; and those who were aged younger than 10 years with stage IV FOXO1-negative disease with distant metastases. Eligible patients had to have a Lansky performance status score of 50 or higher if 16 years or younger and a Karnofsky performance status score of 50 or higher if older than 16 years; all patients were previously untreated. Patients were randomised (1:1) in blocks of four and stratified by histology, stage, and group. Patients received intravenous VAC/VI chemotherapy with a cyclophosphamide dose of 1·2 g/m2 per dose per cycle with or without a reducing dose of intravenous weekly temsirolimus starting at 15 mg/m2 or 0·5 mg/kg per dose for those who weighed less than 10 kg. The total duration of therapy was 42 weeks followed by 6 months of maintenance therapy with oral cyclophosphamide plus intravenous vinorelbine for all patients. Temsirolimus was withheld during radiotherapy and for 2 weeks before any major surgical procedure. The primary endpoint was 3-year event-free survival. Data were analysed with a revised intention-to-treat approach. The study is registered with ClinicalTrials.gov (NCT02567435) and is complete. FINDINGS: Between May 23, 2016, and Jan 1, 2022, 325 patients were enrolled. In 297 evaluable patients (148 assigned to VAC/VI alone and 149 assigned to VAC/VI with temsirolimus), the median age was 6·3 years (IQR 3·0-11·3); 33 (11%) patients were aged 18 years or older; 179 (60%) of 297 were male. 113 (77%) of 148 patients were FOXO1 negative in the VAC/VI group, and 108 (73%) of 149 were FOXO1 negative in the VAC/VI with temsirolimus group. With a median follow-up of 3·6 years (IQR 2·8-4·5), 3-year event-free survival did not differ significantly between the two groups (64·8% [95% CI 55·5-74·1] in the VAC/VI group vs 66·8% [57·5-76·2] in the VAC/VI plus temsirolimus group (hazard ratio 0·86 [95% CI 0·58-1·26]; log-rank p=0·44). The most common grade 3-4 adverse events were anaemia (62 events in 60 [41%] of 148 patients in the VAC/VI group vs 89 events in 87 [58%] of 149 patients in the VAC/VI with temsirolimus group), lymphopenia (83 events in 65 [44%] vs 99 events in 71 [48%]), neutropenia (160 events in 99 [67%] vs 164 events in 105 [70%]), and leukopenia (121 events in 86 [58%] vs 132 events in 93 [62%]). There was one treatment-related death in the VAC/VI with temsirolimus group, categorised as not otherwise specified. INTERPRETATION: Addition of temsirolimus to VAC/VI did not improve event-free survival in patients with intermediate-risk rhabdomyosarcoma defined by their FOXO1 translocation status and clinical factors. Novel biology-based strategies are needed to improve outcomes in this population. FUNDING: The Children's Oncology Group (supported by the US National Cancer Institute, US National Institutes of Health).
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique , Cyclophosphamide , Rhabdomyosarcome , Sirolimus , Vincristine , Humains , Mâle , Femelle , Enfant , Adolescent , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Sirolimus/analogues et dérivés , Sirolimus/administration et posologie , Sirolimus/usage thérapeutique , Rhabdomyosarcome/traitement médicamenteux , Rhabdomyosarcome/mortalité , Rhabdomyosarcome/anatomopathologie , Enfant d'âge préscolaire , Vincristine/administration et posologie , Vincristine/effets indésirables , Jeune adulte , Cyclophosphamide/administration et posologie , Adulte , Dactinomycine/administration et posologie , Irinotécan/administration et posologie , Irinotécan/usage thérapeutique , Nourrisson , Survie sans progression , Protéine O1 à motif en tête de fourche/génétiqueRÉSUMÉ
Chemotherapy-induced peripheral neuropathy (CIPN) and associated pain are prevalent adverse effects of pediatric cancer treatment, significantly affecting the patient's quality of life. Their impact and risk factors have yet to be assessed in our country. This study aimed to assess the prevalence and clinical characteristics of CIPN, as well as to explore associations with patient- and treatment-related variables, within a cohort of Argentinean pediatric oncology patients. Sixty-six patients diagnosed with malignant hematopoietic tumors and receiving the neurotoxic agent vincristine were included in this observational study. Variables analyzed included age, gender, anthropometric measurements, tumor type, chemotherapy treatment, development of pain and other symptoms, severity, and analgesic treatment. The study population consisted of 39 boys and 27 girls. Most patients received two or three neurotoxic drugs. Symptoms consistent with CIPN were identified in 15 children, reflecting a prevalence of 23%. The main symptom was pain in the lower limbs, with some patients reporting jaw or generalized body pain. Pain was categorized as moderate or severe in 60% and 27% of cases, respectively. NSAIDs, anticonvulsants, and/or opioids were prescribed. Among the patient- and treatment-related variables analyzed as potential risk factors, the use of vincristine in conjunction with cytarabine and the administration of a higher number of neurotoxic drugs demonstrated significant association with the development of CIPN. CONCLUSIONS: Combination therapy stands out as a risk factor for clinical CIPN. The high prevalence of moderate/severe pain underscores the importance of close vigilance given its potential to compromise the patient's overall well-being. WHAT IS KNOWN: ⢠Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent adverse effect and dose-limiting factor in pediatric cancer treatment. ⢠Prevalence varies among regions and risk factors are still under study. WHAT IS NEW: ⢠Prevalence of symptomatic CIPN is 23% among pediatric patients undergoing treatment for hematopoietic tumors in a referral hospital in Argentina. Most patients report moderate or severe pain. ⢠Combining vincristine with cytarabine and using a higher number of neurotoxic drugs in combination therapies exhibit significant association with the development of CIPN-related symptoms.
Sujet(s)
Neuropathies périphériques , Vincristine , Humains , Mâle , Femelle , Enfant , Adolescent , Enfant d'âge préscolaire , Neuropathies périphériques/induit chimiquement , Neuropathies périphériques/épidémiologie , Vincristine/effets indésirables , Argentine/épidémiologie , Facteurs de risque , Prévalence , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Douleur/traitement médicamenteux , Douleur/épidémiologie , Douleur/étiologie , Nourrisson , Qualité de vie , Mesure de la douleurRÉSUMÉ
Importance: Options for adults with relapsed or refractory B-cell acute lymphoblastic leukemia or lymphoma (B-ALL) are limited, and new approaches are needed. Inotuzumab ozogamicin (InO) has been combined with low-intensity chemotherapy, with modest improvements over historical controls, and dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) treatment is safe and active for newly diagnosed ALL. Objective: To assess the safety and clinical activity of DA-EPOCH and InO in adults with relapsed or refractory B-ALL. Design, Setting, and Participants: This single-center, single-arm, nonrandomized, phase 1 dose-escalation trial included adults with relapsed or refractory CD22+ B-ALL and was conducted between September 2019 and November 2022. At least 5% blood or marrow blasts or measurable extramedullary disease (EMD) was required for enrollment. Interventions: DA-EPOCH was given on days 1 to 5, while InO was given on day 8 and day 15 of a 28-day cycle. Three dose levels were studied using a bayesian optimal interval design. Main Outcomes and Measures: The primary outcome was the maximum tolerated dose of InO when combined with DA-EPOCH, defined as the highest dose level that produced a rate of dose-limiting toxicity below 33%. Secondary objectives included response rates, survival estimates, and descriptions of toxic effects. Results: A total of 24 participants were screened and enrolled (median age, 46 [range, 28-76] years; 15 [62%] male). The median number of lines of prior therapy was 3 (range, 1-12). Three of 11 participants (27%) treated at the highest dose level (InO, 0.6 mg/m2, on day 8 and day 15) experienced dose-limiting toxicity, making this the maximum tolerated dose. No deaths occurred during the study, and only 1 patient (4%; 95% CI, 0.1%-21%) developed sinusoidal obstructive syndrome after poststudy allograft. The morphologic complete response rate was 84% (95% CI, 60%-97%), 88% (95% CI, 62%-98%) of which was measurable residual disease negative by flow cytometry. Five of 6 participants with EMD experienced treatment response. The overall response rate was 83% (95% CI, 63%-95%). Median overall survival, duration of response, and event-free survival were 17.0 (95% CI, 8.4-not reached), 15.0 (95% CI, 6.7-not reached), and 9.6 (95% CI, 4.5-not reached) months, respectively. Conclusions: In this study, adding InO to DA-EPOCH in adults with relapsed or refractory B-ALL was feasible, with high response rates and sinusoidal obstructive syndrome occurring rarely in a heavily pretreated population. Many patients were able to proceed to poststudy consolidative allogeneic hematopoietic cell transplant and/or chimeric antigen receptor T-cell therapy. Further investigation of this combination is warranted. Trial Registration: ClinicalTrials.gov Identifier: NCT03991884.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique , Cyclophosphamide , Doxorubicine , Étoposide , Inotuzumab ozogamicine , Prednisone , Vincristine , Humains , Inotuzumab ozogamicine/administration et posologie , Mâle , Femelle , Adulte d'âge moyen , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Protocoles de polychimiothérapie antinéoplasique/administration et posologie , Adulte , Étoposide/administration et posologie , Étoposide/effets indésirables , Doxorubicine/administration et posologie , Doxorubicine/effets indésirables , Cyclophosphamide/administration et posologie , Cyclophosphamide/usage thérapeutique , Cyclophosphamide/effets indésirables , Vincristine/administration et posologie , Vincristine/effets indésirables , Vincristine/usage thérapeutique , Prednisone/administration et posologie , Prednisone/effets indésirables , Prednisone/usage thérapeutique , Sujet âgé , Leucémie-lymphome lymphoblastique à précurseurs B/traitement médicamenteux , Leucémie-lymphome lymphoblastique à précurseurs B/mortalité , Leucémie-lymphome lymphoblastique à précurseurs B/anatomopathologie , Dose maximale tolérée , Relation dose-effet des médicamentsRÉSUMÉ
This study aimed to investigate changes in hand sensation (finger tactile threshold and two-point discrimination) and function in patients with malignant lymphoma, particularly during the early stages of chemotherapy with vincristine. Eighteen patients with malignant lymphoma were enrolled in this study. Data on the Common Terminology Criteria for Adverse Events Version 4.0, the visual analog scale for hand numbness, the Semmes Weinstein monofilament test, static and moving two-point discrimination (2PD), grip strength, pinch strength, and the Purdue Pegboard test were collected at 3 time points: before the start of chemotherapy (T0), after the first cycle of chemotherapy (T1), and after the second cycle of chemotherapy (T2). No significant changes were observed in Semmes Weinstein monofilament test at T0, T1, or T2 in either hand. However, the static 2PD was significantly worse for the right ring, little, and left middle fingers, whereas the moving 2PD was significantly worse for the right ring, left index, middle, and ring fingers. Furthermore, the visual analog scale scores for hand numbness and left-hand grip strength worsened significantly. Right-hand grip strength, pinch strength of both hands, and Purdue Pegboard test showed no significant deterioration. Chemotherapy with vincristine may affect hand sensation and function in patients with malignant lymphoma by exacerbating finger 2PD and hand numbness. Additionally, during the early stages of vincristine chemotherapy, it is important to monitor for a decrease in grip strength specifically in the left hand.
Sujet(s)
Force de la main , Main , Lymphomes , Vincristine , Humains , Vincristine/effets indésirables , Vincristine/administration et posologie , Mâle , Femelle , Adulte d'âge moyen , Lymphomes/traitement médicamenteux , Sujet âgé , Adulte , Antinéoplasiques d'origine végétale/effets indésirables , Antinéoplasiques d'origine végétale/administration et posologie , Hypoesthésie/induit chimiquementRÉSUMÉ
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma, for which cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab(R-CHOP) is one of the standard regimens. Given that R-CHOP is highly emetogenic, chemotherapy-induced nausea and vomiting (CINV) prevention is clinically important. However, there is a paucity of studies focusing on these patients. This study aimed to ascertain the effectiveness of an oral fixed-dose combination of netupitant and palonosetron (NEPA) in preventing CINV in patients with DLBCL undergoing first-line R-CHOP chemotherapy. Seventy patients were enrolled in this single-center prospective non-comparative study conducted between November 2020 and May 2023 in South Korea. NEPA was administered 1 h prior to chemotherapy initiation on day 1. The primary endpoint of the study was the complete response rate (no emesis, and no rescue medication) during the acute, delayed, and overall phases, which were assessed over a period of 120 h post-chemotherapy. The complete response rates for NEPA were 90.0% [95% CI 80.5, 95.9] for the acute phase, 85.7% [95% CI 75.3, 92.9] for the delayed phase, and 84.3% [95% CI 73.6, 91.9] for the overall phase, with no-emesis rates (acute: 97.1% [95% CI 97.1, 99.7], delayed: 95.7% [95% CI 88.0, 99.1], overall: 92.9% [95% CI 84.1, 97.6]). NEPA was well tolerated with no severe treatment-emergent adverse events. NEPA exhibited substantial efficacy in mitigating CINV in DLBCL patients undergoing R-CHOP chemotherapy, demonstrating high CR and no-emesis rates, and favorable safety profiles.
Sujet(s)
Antiémétiques , Protocoles de polychimiothérapie antinéoplasique , Cyclophosphamide , Doxorubicine , Lymphome B diffus à grandes cellules , Nausée , Palonosétron , Prednisone , Rituximab , Vincristine , Vomissement , Humains , Lymphome B diffus à grandes cellules/traitement médicamenteux , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Doxorubicine/effets indésirables , Doxorubicine/administration et posologie , Cyclophosphamide/effets indésirables , Cyclophosphamide/usage thérapeutique , Cyclophosphamide/administration et posologie , Mâle , Femelle , Adulte d'âge moyen , Vincristine/effets indésirables , Vincristine/usage thérapeutique , Vincristine/administration et posologie , Nausée/prévention et contrôle , Nausée/induit chimiquement , Vomissement/prévention et contrôle , Vomissement/induit chimiquement , Rituximab/effets indésirables , Rituximab/usage thérapeutique , Rituximab/administration et posologie , Prednisone/effets indésirables , Prednisone/administration et posologie , Prednisone/usage thérapeutique , Sujet âgé , Palonosétron/usage thérapeutique , Palonosétron/administration et posologie , Adulte , Études prospectives , Antiémétiques/usage thérapeutique , Antiémétiques/administration et posologie , Pyridines/effets indésirables , Pyridines/administration et posologie , Pyridines/usage thérapeutique , Résultat thérapeutique , Association médicamenteuse , Isoquinoléines , QuinuclidinesRÉSUMÉ
ABSTRACT: Posttransplant lymphoproliferative disorder (PTLD) is a rare complication of solid organ transplantation, and cytotoxic chemotherapy is associated with treatment-related morbidity and mortality. Current treatment takes a sequential, risk-stratified approach, and patients with low-risk disease after initial immunotherapy can avoid escalation to immunochemotherapy. TIDaL is a prospective, single-arm phase 2 trial investigating the activity and tolerability of ibrutinib combined with risk-stratified therapy for first-line treatment of PTLD. Eligible patients were adults with newly diagnosed CD20+ B-cell PTLD after solid organ transplant and performance status 0 to 2. Initial treatment comprised 49 days of ibrutinib 560 mg once daily, with 4 doses of weekly rituximab. Treatment response on interim scan and baseline International Prognostic Index were used to allocate patients to either a low-risk arm (who continued ibrutinib, alongside 4 further doses of 3-weekly rituximab) or high-risk (escalation to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] immunochemotherapy, with ibrutinib continuing in patients aged <65 years). The primary outcome was complete response on interim scan, achieved by 11 of 38 patients (29%; 95% confidence interval [CI], 15-46). This did not reach the prespecified threshold for clinically significant activity. Secondary outcomes included allocation to the low-risk arm (41% of patients), 2-year progression-free survival (58%; 95% CI, 44-76), and 2-year overall survival (76%; 95% CI, 63-91). Adverse events were mostly hematological, gastrointestinal, and infective. Although TIDaL does not support adding ibrutinib into first-line treatment of PTLD, increasing the proportion of patients who can be treated without cytotoxic chemotherapy remains an important aim of future research. This trial was registered at www.clinicaltrials.gov as #ISRCTN32667607.
Sujet(s)
Adénine , Protocoles de polychimiothérapie antinéoplasique , Syndromes lymphoprolifératifs , Pipéridines , Rituximab , Humains , Pipéridines/usage thérapeutique , Pipéridines/effets indésirables , Pipéridines/administration et posologie , Adulte d'âge moyen , Femelle , Mâle , Adénine/analogues et dérivés , Adénine/usage thérapeutique , Syndromes lymphoprolifératifs/traitement médicamenteux , Syndromes lymphoprolifératifs/étiologie , Sujet âgé , Adulte , Rituximab/effets indésirables , Rituximab/administration et posologie , Rituximab/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Transplantation d'organe/effets indésirables , Cyclophosphamide/administration et posologie , Cyclophosphamide/usage thérapeutique , Cyclophosphamide/effets indésirables , Vincristine/administration et posologie , Vincristine/effets indésirables , Vincristine/usage thérapeutique , Doxorubicine/effets indésirables , Doxorubicine/usage thérapeutique , Doxorubicine/administration et posologie , Prednisone/administration et posologie , Prednisone/effets indésirables , Prednisone/usage thérapeutique , Études prospectives , Pyrazoles/usage thérapeutique , Pyrazoles/effets indésirables , Pyrazoles/administration et posologieRÉSUMÉ
Late toxicities can impact survivorship in patients with classical Hodgkin lymphoma (cHL) with pulmonary toxicity after bleomycin-containing chemotherapy being a concern. The incidence of pulmonary diseases was examined in this Danish population-based study. A total of 1474 adult patients with cHL treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or BEACOPP (bleomycin, vincristine, etoposide, doxorubicin, cyclophosphamide, procarbazine and prednisone) between 2000 and 2018 were included along with 7370 age- and sex-matched comparators from the background population. Median follow-up was 8.6 years for the patients. Patients with cHL had increased risk of incident pulmonary diseases (HR 2.91 [95% CI 2.30-3.68]), with a 10-year cumulative risk of 7.4% versus 2.9% for comparators. Excess risks were observed for interstitial lung diseases (HR 15.84 [95% CI 9.35-26.84]) and chronic obstructive pulmonary disease (HR 1.99 [95% CI 1.43-2.76]), with a 10-year cumulative risk of 4.1% and 3.5% respectively for patients. No excess risk was observed for asthma (HR 0.82 [95% CI 0.43-1.56]). Risk factors for interstitial lung diseases were age ≥60 years, the presence of B-symptoms and low albumin. These findings document a significant burden of pulmonary diseases among patients with cHL and emphasize the importance of diagnostic work-up of pulmonary symptoms.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique , Maladie de Hodgkin , Maladies pulmonaires , Humains , Maladie de Hodgkin/épidémiologie , Maladie de Hodgkin/traitement médicamenteux , Femelle , Mâle , Adulte , Danemark/épidémiologie , Adulte d'âge moyen , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Maladies pulmonaires/induit chimiquement , Maladies pulmonaires/épidémiologie , Maladies pulmonaires/étiologie , Sujet âgé , Bléomycine/effets indésirables , Bléomycine/administration et posologie , Jeune adulte , Incidence , Procarbazine/effets indésirables , Procarbazine/administration et posologie , Vincristine/effets indésirables , Vincristine/usage thérapeutique , Vincristine/administration et posologie , Études de cohortes , Cyclophosphamide/effets indésirables , Cyclophosphamide/usage thérapeutique , Cyclophosphamide/administration et posologie , Adolescent , Doxorubicine/effets indésirables , Doxorubicine/usage thérapeutique , Doxorubicine/administration et posologieRÉSUMÉ
BACKGROUND: Traditional dosing of chemotherapy drugs based on body surface area may overdose small dogs, leading to an increased frequency of adverse events (AEs). HYPOTHESIS/OBJECTIVES: Evaluate the frequency of hematologic and gastrointestinal AEs in dogs with newly diagnosed lymphoma treated with vincristine weighing ≤15 kg in comparison to dogs weighing >15 kg. We hypothesized that dogs weighing ≤15 kg would experience a higher frequency of AEs. ANIMALS: One hundred and thirty-eight dogs with newly diagnosed lymphoma were treated with vincristine. METHODS: A multicenter retrospective study reviewing hematologic data and medical record information. Complete blood counts were performed no more than 24 hours before vincristine administration and then between 4 and 8 days post-administration. Data were evaluated using logistic regression or ordinal logistic regression. RESULTS: Thirty-eight dogs weighing ≤15 kg and 100 dogs weighing >15 kg were included. The median vincristine dose for both groups was 0.6 mg/m2. Seventeen (12.3%) instances of neutropenia occurred with no significant difference in overall frequency or grade between groups. Thirty initially asymptomatic substage A dogs (29.4%) experienced gastrointestinal AEs. Because of the widespread use of gastrointestinal supportive care medications, statistical comparison between groups could not be performed. Seven instances of hospitalization occurred (5.0%) and the risk of hospitalization did not differ significantly between groups (P = .37). CONCLUSIONS AND CLINICAL IMPORTANCE: Vincristine dosed at ≤0.6 mg/m2 does not increase the risk of hematologic AEs in dogs weighing ≤15 kg.
Sujet(s)
Antinéoplasiques d'origine végétale , Poids , Maladies des chiens , Lymphomes , Vincristine , Animaux , Chiens , Maladies des chiens/induit chimiquement , Maladies des chiens/traitement médicamenteux , Vincristine/effets indésirables , Vincristine/usage thérapeutique , Vincristine/administration et posologie , Lymphomes/médecine vétérinaire , Lymphomes/traitement médicamenteux , Études rétrospectives , Mâle , Femelle , Poids/effets des médicaments et des substances chimiques , Antinéoplasiques d'origine végétale/effets indésirables , Antinéoplasiques d'origine végétale/usage thérapeutique , Neutropénie/induit chimiquement , Neutropénie/médecine vétérinaireRÉSUMÉ
BACKGROUND: Rhabdomyosarcoma (RMS) is a rare cancer that develops in soft tissue, particularly skeletal muscle tissue and occasionally hollow organs like the bladder or uterus. Vincristine (VCR) is the main therapy used in treatment of RMS, it is an alkaloid produced from vinca and it is one of the most commonly prescribed drugs in pediatric oncology for the treatment of a number of tumors. The CYP3A5 enzyme is responsible for vincristine metabolism. The effect of CYP3A5 genetic polymorphism on the efficacy and toxicity of VCR on RMS patients still needs further research. METHODS: Genotyping for CYP3A5 SNPs rs776746, rs10264272 and rs41303343 was performed using Taqman Real-Time PCR assays in a retrospective cohort study of 150 RMS pediatric patients treated with vincristine. The relationship between these genotypes and RMS survival was then examined. RESULTS: We found that patients with CYP3A5*3/*3 had the highest incidence of vincristine-induced neuropathy reaching 61.3%. Patients with CYP3A5*1/*3, CYP3A5*3/*6 and the normal metabolizers with CYP3A5*1/*1 had frequencies of 22%, 10.7%, and 4.7%. patients with the lowest frequency of 1.3% were those with the CYP3A5*1/*6 genotype. There was no correlation between the genotypes of CYP3A5*3, CYP3A5*6, CYP3A5*7, and RMS survival. Initial risk, metastasis, response, convulsions, unsteady gait and hepatotoxicity grade had a significant effect on overall survival with p<0.05. CONCLUSION: CYP3A5*1/*1 have less severe vincristine-induced neuropathy than CYP3A5 *1/*3, CYP3A5 *1/*6 and CYP3A5 *3/*3, CYP3A5 *3/*6. There is a significant influence of CYP3A5 mutation on neuropathy grade and assist of ADL as a part of neurotoxicity.
Sujet(s)
Antinéoplasiques d'origine végétale , Cytochrome P-450 CYP3A , Polymorphisme de nucléotide simple , Rhabdomyosarcome , Vincristine , Humains , Vincristine/effets indésirables , Cytochrome P-450 CYP3A/génétique , Femelle , Mâle , Études rétrospectives , Rhabdomyosarcome/génétique , Rhabdomyosarcome/traitement médicamenteux , Rhabdomyosarcome/anatomopathologie , Enfant , Enfant d'âge préscolaire , Égypte , Pronostic , Antinéoplasiques d'origine végétale/effets indésirables , Études de suivi , Taux de survie , Génotype , Nourrisson , AdolescentRÉSUMÉ
The frontline immuno-chemotherapy regimen for HIV-associated non-Hodgkin Lymphoma is dose-adjusted EPOCH ± R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab). Chemotherapy-induced peripheral neuropathy (CIPN), caused by vincristine, is a common adverse effect of EPOCH ± R, negatively impacting long-term patient outcomes. The primary objective of this study was to determine the incidence of CIPN, stratified by HIV status, in patients treated with EPOCH ± R. A retrospective cohort study at a tertiary referral comprehensive cancer center evaluated patients treated with EPOCH ± R from 2011 to 2018. The final sample included 27 patients with HIV compared to 279 without HIV (total n = 306). Overall, the incidence of CIPN was 29.4% (n = 90), including 5 with HIV (18.5%) and 85 without HIV (30.5%). Propensity scores were used to match patients by HIV status. Although no relationship was found between HIV status and neuropathy, CIPN affects too many undergoing treatments for lymphoma, supporting future investigations to minimize toxicities.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique , Cyclophosphamide , Doxorubicine , Étoposide , Infections à VIH , Lymphome malin non hodgkinien , Neuropathies périphériques , Prednisone , Rituximab , Vincristine , Humains , Neuropathies périphériques/induit chimiquement , Neuropathies périphériques/épidémiologie , Neuropathies périphériques/diagnostic , Mâle , Femelle , Études rétrospectives , Adulte d'âge moyen , Cyclophosphamide/effets indésirables , Cyclophosphamide/usage thérapeutique , Lymphome malin non hodgkinien/traitement médicamenteux , Lymphome malin non hodgkinien/épidémiologie , Lymphome malin non hodgkinien/complications , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Vincristine/effets indésirables , Vincristine/usage thérapeutique , Rituximab/effets indésirables , Rituximab/administration et posologie , Doxorubicine/effets indésirables , Doxorubicine/usage thérapeutique , Prednisone/effets indésirables , Prednisone/usage thérapeutique , Infections à VIH/traitement médicamenteux , Infections à VIH/complications , Étoposide/effets indésirables , Étoposide/administration et posologie , Étoposide/usage thérapeutique , Adulte , Sujet âgé , IncidenceRÉSUMÉ
BACKGROUND: Decades following the introduction of vincristine as treatment for haematological malignancies, vincristine-induced peripheral neuropathy (VIPN) remains a pervasive, untreatable side-effect. However there remains a gap in understanding the characteristics of VIPN in adults. This study presents a comprehensive phenotyping of VIPN. METHODS: Adult patients (n = 57; age = 59.8 ± 14.6) were assessed cross-sectionally following completion of vincristine (months post treatment = 16.3 ± 15.6, cumulative dose = 7.6 ± 4.4), with a subset of 20 patients assessed prospectively during treatment. Patient reported measures (EORTC-QLQ-CIPN20, R-ODS) were used to profile symptoms and disability. Neurological assessment was undertaken using the Total Neuropathy Score and nerve conduction studies. Sensory threshold and fine motor tasks were also undertaken. Comparisons of data between timepoints were calculated using paired-sample t tests or Wilcoxon matched-pairs signed-rank test. Comparisons between outcome measures were calculated with independent sample t tests or Mann-Whitney U tests for non-parametric data. RESULTS: The majority of patients developed VIPN by mid-treatment (77.8%, 7.0 ± 3.3 weeks post baseline) with the prevalence remaining stable by end-of-treatment (75%, 8.1 ± 1.7 weeks post mid-treatment). By 3 months post-completion, 50% of patients still reported VIPN although there were significant improvements on neurological grading and functional assessment (P < 0.05). VIPN presented with sensorimotor involvement in upper and lower limbs and was associated with decreased sensory and motor nerve amplitudes, reduced fine-motor function and increased disability. CONCLUSION: VIPN in adults presents as a sensorimotor, upper- and lower-limb neuropathy that significantly impacts disability and function. Neuropathy recovery occurs in a proportion of patients; however, VIPN symptoms may persist and continue to affect long-term quality of life.
Sujet(s)
Tumeurs hématologiques , Neuropathies périphériques , Adulte , Humains , Adulte d'âge moyen , Sujet âgé , Qualité de vie , Vincristine/effets indésirables , Neuropathies périphériques/induit chimiquement , Membre inférieurRÉSUMÉ
Follicular lymphoma (FL) is an indolent lymphoma that becomes aggressive due to histological transformation (HT), leading to reduced survival. Patients with FL have different clinical courses and various treatment options. Some patients exhibit shorter survival and experience disease progression within 24 months of diagnosis/treatment (POD24); the optimal treatment remains an unmet needs. Thus, identifying factors that predict shorter survival is essential to stratify treatment and prolong the survival of patients with FL. To analyze risk factors for POD24 and HT in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line treatment, we performed this post-hoc analysis of patients with advanced indolent B-cell lymphoma in a randomized clinical trial wherein six cycles of R-CHOP were administered every 2-3 weeks. The primary analysis showed no differences in outcomes, which enabled the analysis of 248 patients with FL, assigned to two arms. All histopathological specimens from the 300 enrolled patients were reviewed by three expert hematopathologists. Multivariable analysis implicated Follicular Lymphoma International Prognostic Index (FLIPI) intermediate (odds ratio [OR] 2.531, 95% confidence interval [CI] 0.676-9.466) and high- (OR 2.236, 95% CI 0.160-31.226) risks, B symptoms (OR 2.091, 95% CI 0.747-5.851), and grade 3A (G3A) (OR 1.833, 95% CI 0.634-5.299) as risk factors for POD24. Furthermore, multivariable analysis through a median follow-up of 15.9 years implicated G3A (OR 2.628, 95% CI 0.806-8.575) and high-risk FLIPI (OR 4.401, 95% CI 0.186-104.377) as risk factors for HT. However, an analysis limited to the first 10 years revealed that the prognostic factors elucidated from the longer-term analysis had a greater impact on HT. G3A and high-risk FLIPI may independently predict POD24 and HT, thereby informing treatment stratification of patients with untreated advanced-stage FL in future trials, particularly to address the unmet needs of patients with POD24.